FDA approves Takeda's Mimrylo for polycythemia vera
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 31, 2026
The approval provides Takeda with a new blockbuster drug to offset revenue declines from patent expirations, potentially boosting its earnings growth. Protagonist's stock has nearly tripled over the past year, and the milestone payments strengthen its financial position. The broad label and high efficacy could disrupt the polycythemia vera treatment market, impacting competitors like Incyte and PharmaEssentia.
The U.S. United States — Food and Drug Administration approved rusfertide, a first-in-class drug developed by AnBogen Therapeutics and commercialized by Takeda Pharmaceutical Company, for the treatment of polycythemia vera, a rare blood cancer. The drug, branded as Mimrylo, is a once-weekly injection that mimics the hormone hepcidin to control red blood cell production. The approval was based on Phase 3 data showing that 76.9% of patients did not require therapeutic phlebotomy over 32 weeks, compared to 32.9% in the placebo group. Mimrylo received a broad label without requiring prior treatment. Takeda projects peak sales of $1-2 billion, while Jefferies analyst Stephen Barker forecasts up to $2 billion. Protagonist received $275 million in payments related to the approval and is eligible for up to $875 million more plus royalties. The approval follows Takeda's earlier clearance of narcolepsy drug Orzeyful and precedes expected approval of zasocitinib. Additionally, PharmaEssentia's Besremi received FDA approval for essential thrombocythemia, expanding its label beyond polycythemia vera.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard